The MHRA is consulting with UK stakeholders to gather feedback and comments on a new international guideline for the appropriate inclusion and/or retention of pregnant and/or breast-feeding individuals in clinical trials of medicines.
Similar Posts
Field Safety Notices: 15 – 19 December 2025
List of Field Safety Notices (FSNs) for week 15 – 19 December 2025
Valproate – reproductive risks
Information about the reproductive risks of taking valproate medicines and the measures in place to reduce potential harm.
Guidance: AI Airlock Sandbox Pilot Programme Report
The MHRA’s AI Airlock pilot phase ran between April 2024 and March 2025. This report does not constitute formal MHRA guidance.
Borderline products: how to tell if your product is a medicine
How the MHRA makes decisions on what is a medicinal product (borderline products).
MHRA scientists contribute to international study on novel oral polio vaccine stability
Study confirms vaccine being used in global efforts to achieve and sustain polio eradication is successfully interrupting polio outbreaks whilst minimising risk of new vaccine-derived outbreaks in Uganda